CN108295128B - 一种治疗类风湿关节炎的中药复方制剂及其制备方法 - Google Patents
一种治疗类风湿关节炎的中药复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN108295128B CN108295128B CN201810393645.4A CN201810393645A CN108295128B CN 108295128 B CN108295128 B CN 108295128B CN 201810393645 A CN201810393645 A CN 201810393645A CN 108295128 B CN108295128 B CN 108295128B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- rheumatoid arthritis
- parts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 230000005484 gravity Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 239000006072 paste Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 8
- 241000382455 Angelica sinensis Species 0.000 abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 5
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 4
- 235000006533 astragalus Nutrition 0.000 abstract description 4
- 201000008482 osteoarthritis Diseases 0.000 abstract description 3
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 abstract description 2
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 2
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 abstract description 2
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 abstract description 2
- 229930002966 sinomenine Natural products 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 2
- 239000008669 duhuo Substances 0.000 abstract 2
- 229940010454 licorice Drugs 0.000 abstract 2
- 210000004233 talus Anatomy 0.000 abstract 2
- 241000202807 Glycyrrhiza Species 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- 241000700159 Rattus Species 0.000 description 17
- 206010042674 Swelling Diseases 0.000 description 11
- 210000001503 joint Anatomy 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 208000006820 Arthralgia Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 206010023232 Joint swelling Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000009636 Huang Qi Substances 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002437 synoviocyte Anatomy 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001111421 Pannus Species 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 3
- 241000501743 Gentiana macrophylla Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000005222 synovial tissue Anatomy 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 1
- ZSNUDGRHURTQAA-UHFFFAOYSA-N 2-(2-oxopentyl)benzoic acid Chemical compound C(C(CCC)=O)C1=C(C(=O)O)C=CC=C1 ZSNUDGRHURTQAA-UHFFFAOYSA-N 0.000 description 1
- FBUKMFOXMZRGRB-YFHOEESVSA-N 9(10)-EpOME Chemical compound CCCCC\C=C/CC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-YFHOEESVSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 241000830536 Tripterygium wilfordii Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002875 effect on osteoarthritis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000015398 thunder god vine Nutrition 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种治疗类风湿关节炎的中药复方制剂及其制备方法,属于中药制剂技术领域。治疗类风湿关节炎的中药复方制剂的有效成分由6~15份青风藤、6~12份当归、6~12份白芍、3~10份独活、3~10份秦艽、3~10份桂枝、9~15份黄芪和2~10份甘草制得。本发明的治疗类风湿关节炎的中药复方制剂,选择青藤碱、当归、白芍、独活、秦艽、桂枝、黄芪、甘草中药配伍,将这些药物组合使得各药物功效产生协同作用,从而能够有效治疗早、中、晚期的类风湿关节炎,疗效好,副作用小。对骨性关节炎也有一定的治疗作用。
Description
技术领域
本发明属于中药制剂技术领域,具体是涉及一种治疗类风湿关节炎的中药复方制剂及其制备方法。
背景技术
类风湿性关节炎(RA)是一种以关节病变为主的全身性自身免疫病,又是一种常见病、非化脓性、多发性的关节病,临床发病率较高、危害性较大。且其在各年龄组人群中皆可发病,发病率随年龄增长而增高。目前风湿性疾病在中国内地发病正在逐年增加,其中最严重的类风湿性关节炎,患者已超过440万,RA关节炎的病理主要有滑膜衬里细胞增生、间质大量炎性细胞浸润,以及微血管的新生、血管翳的形成及软骨和骨组织的破坏等。类风湿关节炎多发于青壮年,女性多于男性,起病缓慢,病人有乏力、低热、食欲差、手脚凉等早期症状,此后多数病人出现对称性关节炎,受累关节以末端小关节显著,进而侵犯大关节至关节肿胀、疼痛和僵硬。类风湿关节炎患者随病情发展,会发生关节骨质破坏、永久受损、变形,削弱生活自理能力。以往对该类疾病缺乏有效诊疗手段,又因其多为慢性病程,一般人们对该类疾病认识不够,且由于病因未明,所以治法繁多,疗效欠佳,常用西医消炎镇痛药和激素治疗,开始可能能暂时止痛,但随时间推移逐渐出现关节畸形以致残疾,甚至出现内脏损害,严重可危及生命。
由于西药治疗副作用大,因此人们对有效治疗类风湿性关节炎的中药药物存在极大的需求,我国用于治疗类风湿关节炎使用较多的中药主要为雷公藤药物,但其对心、肝、肾、造血系统、胃肠道、生殖系统等带来的严重副作用令很多患者难以坚持。
发明内容
本发明要解决的技术问题为提供一种针对治疗类风湿关节炎的疗效显著的中药复方制剂及其制备方法。
为了实现上述目的,本发明所采用的技术方案为:
一种治疗类风湿关节炎的中药复方制剂,其有效成分由如下重量份的中药原料制得:
各原料药的药效如下:
青风藤,别名大风藤、吹风散、黑防己、排风藤、青防己。苦、辛,平。归肝、脾经。祛风湿,通经络,利小便。用于风湿痹痛,关节肿胀,麻痹瘙痒。
当归,为伞形科植物当归之根。性温味甘辛,入心、肝、脾经,属补血药。具有补血活血、生肌健骨、调经止痛等功效。含有挥发油,亚丁基苯酞,邻羧基苯正戊酮,多种烃类、棕榈酸、肉豆冠酸、维生素和蔗糖等多种成分。药理证明其有抗菌消炎及镇痛等作用。伤科用于跌打损伤早、中期的瘀滞疼痛,具有活血祛瘀止痛等功效。
白芍,苦、酸,微寒。归肝、脾经。养血调经,敛阴止汗,柔肝止痛,平抑肝阳。用于血虚萎黄,月经不调,自汗,盗汗,胁痛,腹痛,四肢挛痛,头痛眩晕。
独活,别名胡王使者、独摇草、独滑、长生草、川独活、肉独活、资历邱独活、巴东独活、香独活、绩独活、大活、山大活。具有祛风,胜湿,散寒,止痛的功效。主治风寒湿痹,腰膝酸痛,手脚挛痛,慢性气管炎,头痛,齿痛。味辛、苦,性微温。归肾、膀胱经。
秦艽,性味苦辛,平,入肝、胃、胆经,有祛风除湿,和血舒筋,清热利尿的功能,治风湿痹痛,筋骨拘挛,黄疸,便血,骨蒸潮热,小儿疳热,小便不利。
桂枝,桂枝,别名玉桂、牡桂、菌桂、筒桂。具有散寒解表,温通经脉,通阳化气的功效。主治风寒表证,寒湿痹痛,四肢厥冷,经闭痛经,症瘕结块,胸痹,心悸,痰饮,小便不利。味辛、甘,性温。归膀胱、心、肺经。
黄芪,味甘,性微温,归肺、脾、肝、肾经。黄芪有益气固表、敛汗固脱托疮生肌、利水消肿之功效。用于治疗气虚乏力,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴,慢性肾炎,蛋白尿,糖尿病等,炙黄芪益气补中,生用固表托疮;
甘草,甘,平。归心、肺、脾、胃经。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
本发明的治疗类风湿关节炎的中药复方制剂,选择青藤碱、当归、白芍、独活、秦艽、桂枝、黄芪、甘草中药配伍,将这些药物组合使得各药物功效产生协同作用,从而能够有效治疗类风湿关节炎,副作用小,且对骨性关节炎也有一定的治疗作用。
本发明的治疗类风湿关节炎的中药复方制剂具有祛风通络,温经通脉,祛风散寒,除湿消肿,舒筋活血,消痰散癖,强筋健骨的功能,治疗类风湿性关节炎的疗程短、见效快、治愈后不易复发,而且价格低廉、不易复发、使用方便。
作为本发明的治疗类风湿关节炎的中药复方制剂的优选技术方案,其有效成分由如下重量份的中药原料制得:
作为本发明的治疗类风湿关节炎的中药复方制剂的进一步优选技术方案,其有效成分由如下重量份的中药原料制得:
本发明治疗类风湿关节炎的中药复方制剂的制备方法,步骤如下:
1)、将8味药材洗净,按比例混合后加6~8倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤,浓缩,得到60℃时比重为1.0-1.2的流浸膏;
2)、采用常规制备工艺,制成任何一种药剂学上所说的剂型,例如凝胶剂、凝胶膏剂、软膏剂、片剂、胶囊剂、颗粒剂、滴丸剂、口服液、丸剂、糖浆剂、分散片或泡腾片等。
附图说明
图1是各组别大鼠关节肿胀度的变化曲线。
图2是各组别炎性因子的变化柱状图。
图3是各组别提取物对组织病理学变化的影响图(HE染色,放大倍数40倍;比例尺500μm)。
具体实施方式
以下结合附图和实施例对本发明的一种治疗类风湿关节炎的中药复方制剂作出进一步的详述。
实施例1
1)、将青风藤9g、当归10g、白芍8g、独活9g、秦艽7g、桂枝5g、黄芪10g和甘草9g洗净,混合后加8倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤,浓缩,得到60℃时比重为1.0的流浸膏;
2)、采用常规制备工艺,制成片剂。
实施例2
1)、将青风藤15g、当归8g、白芍10g、独活7g、秦艽9g、桂枝3g、黄芪13g和甘草7g洗净,混合后加7.5倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤,浓缩,得到60℃时比重为1.05的流浸膏;
2)、采用常规制备工艺,制成凝胶膏剂。
实施例3
1)、将青风藤12g、当归12g、白芍6g、独活3g、秦艽10g、桂枝10g、黄芪9g和甘草2g洗净,混合后加6.5倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤,浓缩,得到60℃时比重为1.1的流浸膏;
2)、采用常规制备工艺,制成胶囊剂
实施例4
1)、将青风藤6g、当归6g、白芍12g、独活10g、秦艽3g、桂枝3g、黄芪15g和甘草10g洗净,混合后加6倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤,浓缩,得到60℃时比重为1.2的流浸膏;
2)、采用常规制备工艺,制成糖浆剂
实施例5
1)、将青风藤12g、当归10g、白芍10g、独活8g、秦艽8g、桂枝3g、黄芪11g和甘草8g洗净,混合后加7倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤,浓缩,得到60℃时比重为1.15的流浸膏;
2)、采用常规制备工艺,制成颗粒剂。
一、动物试验
实验分组与剂量设计:随机挑选健康大鼠8只作为正常组,其余大鼠接受弗氏完全佐剂CFA造模,造模第10天挑选继发病变明显的大鼠24只进行分组,每组8只,随机分为3组:模型组、阳性对照组(25mg/kg)、给药组(1.5g/kg)。
给药时间及方法:取实施例5得到的制剂进行试验:免疫两周后开始按体重灌胃给药,按1.5g/kg(体重),一日一次,连续给药10d。同时,模型组大鼠灌服等容积生理盐水。通过使用体积计测量爪体积来测定爪肿胀。测量是在第0天CFA注射之前获得的,并且之后从第11d到第23d每三天持续进行。
(1)、功效实验
①、大鼠观察:SD大鼠经CFA免疫后,相继出现明显症状,表现为精神萎靡不振,体重下降,行动迟缓、跛行,且其踝关节出现明显肿胀,无死亡。造模两周后,给药组给以相应药物治疗,上述症状减轻,表现为食欲、体重开始增加,关节肿胀程度减轻等。
②、对大鼠关节肿胀程度影响
各组别大鼠关节肿胀度变化见图1(注:给药组采用实施例5制得的药剂;数值表示为平均值)所示。实验结果显示:与正常大鼠相比,在AA大鼠中观察到左后爪肿胀显著增加。给药组关节肿胀程度从第14天开始明显低于模型组(P<0.01);阳性对照组关节肿胀程度低于模型组;与阳性对照组组比较,给药组有明显优势。
(2)、细胞因子检测
许多研究表明,促炎性细胞因子如IL-1β,IL-6和TNF-α在急性和慢性炎症的启动和维持中起重要作用。此外,已经证明TNF-α是IL-1β的重要诱导物,其对于促进RA慢性状态的开始是必需的。相反,通过抑制促炎细胞因子的释放,IL-10一般被认为是一种有效的抗炎细胞因子,其也可以保护关节完整性RA进展。
各组别对炎性因子的影响见图2(注:给药组采用实施例5制得的药剂;数值表示为平均值)所示。实验结果显示:给药组可显著降低AA大鼠血清中IL-1β,IL-6和TNF-α的释放(P<0.001),同时增加IL-10的含量(P<0.001)。
(3)、对AA大鼠组织病理学的影响
对各组大鼠关节病理情况进行综合观察比较,结果见图3所示。
正常组:关节结构正常,滑膜组织无充血水肿,滑膜细胞无增生现象,无血管翳形成,关节软骨表面光滑平整,无剥脱现象,关节软骨下骨小梁大小、排列正常。
模型组:可见明显的滑膜细胞增生,排列紊乱,滑膜组织充血水肿,毛细血管增生,并可见炎细胞浸润;增生的滑膜组织形成绒毛状,可伸向关节腔深处,或向软骨面爬行形成血管翳。在软骨细胞变形,可出现剥脱,未见骨质的破坏。
阳性对照组:病理变化略有改善,效果不如给药组。
给药组:明显减少了这些病理学变化。
总体来看,给药组和阳性对照组均能改善模型大鼠的关节损伤情况(P<0.05),其中给药组疗效优于阳性对照组,与模型组比较,给药组光镜下可见滑膜细胞增生减轻,滑膜组织充血水肿明显减轻,血管增生和浸润炎细胞数量减少,血管翳形成显著减少。关节软骨面可见扁平层剥脱,剥脱软骨面较平整,软骨下骨的骨小梁大小、排列正常。
二、疗效调查
为检验本发明中药复方制剂的治疗效果,选取80例类风湿关节炎者给予本发明上述实施例5制备所得的复方中药颗粒剂治疗;其中男性46例,女性34例,年龄40-65岁,平均年龄54岁。病程0.5-12年。临床表现主要为关节疼痛、关节肿胀、骨质疏松,严重者活动障碍、关节畸形。
疗效评定标准:
(1)、治愈:服用本发明复方中药颗粒剂2个疗程后,关节疼痛、关节肿胀消失,活动障碍、关节畸形部分明显好转;
(2)、有效:服用本发明复方中药颗粒剂2个疗程后,关节疼痛、关节肿胀减轻,活动障碍、关节畸形部分逐步好转;
(3)、无效:服用本发明复方中药颗粒剂2个疗程后,关节疼痛、关节肿胀、活动障碍、关节畸形无任何改善。
疗效评定结果:
80例类风湿关节炎者服用本发明的复方中药颗粒剂2个疗程后,治愈40例,有效39例,无效1例。总有效率十分显著。
三、典型病例
案例1
汪某,男,65岁,退休职工,患类风湿关节炎4年多,双手僵化,疼痛肿胀,血压偏高,经多方医治均无效。服用本发明实施例1的复方中药片剂2个疗程后,关节肿胀、疼痛现象消失,血压基本恢复正常。再继续服用2个疗程,类风湿关节炎逐渐好转。
案例2
汪某,女,63岁,退休干部,一天早上,突然感到浑身不适,站立不稳,家人赶紧送往医院,经检查化验确诊为类风湿关节炎。此后,很快出现全身麻木、四肢无力、疼痛难忍、行走困难。更严重的是各骨节红肿,逐渐变形、僵硬,肌肉萎缩、强直,生活不能自理。虽然采用了多种风湿关节炎的药物和治疗,但一直未见好转。后服用本发明实施例3的复方中药胶囊剂2个疗程后,发现身体麻木感减轻,疼痛感减缓,四肢也能做一些小幅度的动作了。继续服用本发明实施例3的复方中药胶囊剂4个疗程后,关节肿胀、疼痛现象逐渐消失,恢复了生活的自理能力。
案例3
王某,男,55岁,患有关节炎不断疼痛,劳累后加重,关节畸形肿大;久行久站均疼痛,上下楼疼痛加重;下蹲困难,膝关节伸屈功能障碍,影响生活和劳动;拍片报告显示确诊为:膝关节骨性关节炎;其先后到过北京上海等医院进行治疗,治疗效果不明显,后来使用本发明实施例2的复方中药胶凝膏剂外敷治疗,连续服用三个疗程后,双膝行走、上下楼均无疼痛,下蹲活动自如,恢复日常生活和劳动,经医院确诊病情好转。
案例4
夏某,女,52岁,患者行走跛行,左膝疼痛较重,畸形,下蹲困难,不能伸屈,有时突然刺痛,腿软欲跌倒,后被确诊为双膝骨性关节炎;患病4年,曾在省级医院治疗,疗效不佳;采用本发明实施例2的复方中药胶凝膏剂外敷治疗,连续治疗三个月后,经确诊,该患者已治愈,恢复劳动。
案例5
葛某,男,48岁,患有关节炎多年,下蹲困难,有时突然刺痛;经人介绍来我院采用本发明实施例2的复方中药胶凝膏剂外敷治疗,连续治疗二个疗程后,经确诊,该患者已完全治愈。
案例6
袁某,女,40岁,患有四肢小关节对称性疼痛,经查类风湿因子阳性,抗“O”阴性,血沉64mm/h,患者面色苍白,脉象濡缓,喜热怕冷,饮食纳差,舌质红苔白腻,舌底瘀血,球结膜充血,经诊断为“亚急性类风湿”,经实施例5的复方中药颗粒剂进行治疗,连续服用2个疗程后,该患者已完全治愈。
案例7
任某某,男,62岁,膝关节肿胀疼痛且关节局部变形,活动受限。医院诊断为类风湿性关节炎两年余。期间,通过多种方法治疗,效果不好,生活一直很痛苦,严重影响了生活。近期开始服用实施例4的复方中药糖浆剂,连续口服三个疗程,疼痛及症状消失,后又巩固三个疗程。经检查各项指标正常。随访尚无复发。
以上内容仅仅是对本发明的构思所作的举例和说明,所属本技术领域的技术人员对所描述的具体实施例做各种各样的修改或补充或采用类似的方式替代,只要不偏离发明的构思或者超越本权利要求书所定义的范围,均应属于本发明的保护范围。
Claims (4)
4.一种制备如权利要求1或2或3所述治疗类风湿关节炎的中药复方制剂的方法,其特征在于,步骤如下:
1)、将8味药材洗净,按比例混合后加6~8倍重量的70%乙醇回流2次,每次1小时,合并2次提取液,过滤,浓缩,得到60℃时比重为1.0-1.2的流浸膏;
2)、采用常规制备工艺,制成凝胶剂、凝胶膏剂、软膏剂、片剂、胶囊剂、颗粒剂、滴丸剂、口服液、丸剂、糖浆剂、分散片或泡腾片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810393645.4A CN108295128B (zh) | 2018-04-27 | 2018-04-27 | 一种治疗类风湿关节炎的中药复方制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810393645.4A CN108295128B (zh) | 2018-04-27 | 2018-04-27 | 一种治疗类风湿关节炎的中药复方制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108295128A CN108295128A (zh) | 2018-07-20 |
CN108295128B true CN108295128B (zh) | 2021-04-16 |
Family
ID=62846437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810393645.4A Active CN108295128B (zh) | 2018-04-27 | 2018-04-27 | 一种治疗类风湿关节炎的中药复方制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108295128B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108653517A (zh) * | 2018-08-15 | 2018-10-16 | 河南金鹿堂药业有限公司 | 治疗风湿性关节炎的中药贴剂及其制备方法 |
CN115137766B (zh) * | 2022-08-11 | 2023-07-07 | 新疆医科大学 | 一种抗风湿中药制剂的制备方法、中药制剂与应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1712054A (zh) * | 2005-05-24 | 2005-12-28 | 赵东科 | 秦川通痹片 |
CN101816729A (zh) * | 2010-03-03 | 2010-09-01 | 鲍旭刚 | 一种治疗关节炎的药物及其制备方法 |
CN103432217A (zh) * | 2013-08-01 | 2013-12-11 | 重庆市中药研究院 | 一种治疗类风湿性关节炎的外用药物组合物及其制备方法和用途 |
KR101720051B1 (ko) * | 2014-10-29 | 2017-03-28 | 경운대학교 산학협력단 | 독활 발효물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약학 조성물 |
-
2018
- 2018-04-27 CN CN201810393645.4A patent/CN108295128B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1712054A (zh) * | 2005-05-24 | 2005-12-28 | 赵东科 | 秦川通痹片 |
CN101816729A (zh) * | 2010-03-03 | 2010-09-01 | 鲍旭刚 | 一种治疗关节炎的药物及其制备方法 |
CN103432217A (zh) * | 2013-08-01 | 2013-12-11 | 重庆市中药研究院 | 一种治疗类风湿性关节炎的外用药物组合物及其制备方法和用途 |
KR101720051B1 (ko) * | 2014-10-29 | 2017-03-28 | 경운대학교 산학협력단 | 독활 발효물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CN108295128A (zh) | 2018-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103211932B (zh) | 一种治疗风湿痹症的中药组合物 | |
CN103705809A (zh) | 一种治疗痛风的中药 | |
CN103536858A (zh) | 一种治疗类风湿性关节炎的药物 | |
CN103263560B (zh) | 一种补肾通络的中药组合物及其制备方法 | |
CN101040927B (zh) | 一种内服治疗强直性脊柱炎的中药组合物 | |
CN108295128B (zh) | 一种治疗类风湿关节炎的中药复方制剂及其制备方法 | |
CN112755140B (zh) | 一种用于治疗痛风性关节炎的药物组合物及其制备方法和用途 | |
CN103495126B (zh) | 一种治疗风湿病的中药组合物 | |
CN102861296B (zh) | 治疗膝关节滑膜炎的利湿消肿丸 | |
CN101745047A (zh) | 一种治疗痛风病的中药组合物及制备方法 | |
CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
CN104383336B (zh) | 一种用于肾结石术后护理的中药制剂及制备方法 | |
CN103599486B (zh) | 一种内服治疗类风湿性关节炎的中药组合物 | |
CN102430097A (zh) | 一种治疗白癜风的中药 | |
CN104399055A (zh) | 一种治疗肩周炎的中药组合物 | |
CN103585589B (zh) | 一种治疗慢性类风湿性关节炎的药物 | |
CN103550446B (zh) | 一种外用治疗类风湿关节炎的中药组合物及其应用 | |
CN103041362B (zh) | 一种治疗风湿、类风湿的药物及其制备方法 | |
CN104398637A (zh) | 治疗类风湿性关节炎的中药药酒 | |
CN111617175A (zh) | 一种治疗肢体关节疼痛的中药组合物、制备方法及应用 | |
CN105079549A (zh) | 一种治疗狼疮性肾炎的中药 | |
CN103948694A (zh) | 疏风通痹中药及其制备方法 | |
CN103961490A (zh) | 一种治疗风寒湿痹的复方药物及其制备方法 | |
CN103656378A (zh) | 一种治疗急性痛风性关节炎的中药药剂 | |
CN103610914B (zh) | 一种治疗风湿性关节炎的内服中药酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |